KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $8.9 million.

  • Rigel Pharmaceuticals' Other Accumulated Expenses fell 1027.39% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year decrease of 1027.39%. This contributed to the annual value of $10.4 million for FY2024, which is 9490.06% up from last year.
  • Rigel Pharmaceuticals' Other Accumulated Expenses amounted to $8.9 million in Q3 2025, which was down 1027.39% from $8.6 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $17.6 million during Q3 2022, with a 5-year trough of $5.0 million in Q3 2023.
  • Over the past 5 years, Rigel Pharmaceuticals' median Other Accumulated Expenses value was $8.9 million (recorded in 2025), while the average stood at $10.0 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 11257.04% in 2021, then plummeted by 7142.37% in 2023.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Other Accumulated Expenses stood at $13.5 million in 2021, then crashed by 51.98% to $6.5 million in 2022, then fell by 17.75% to $5.3 million in 2023, then skyrocketed by 94.9% to $10.4 million in 2024, then fell by 13.98% to $8.9 million in 2025.
  • Its Other Accumulated Expenses stands at $8.9 million for Q3 2025, versus $8.6 million for Q2 2025 and $7.4 million for Q1 2025.